Interestingly, the percentages of Tregs and CD137+ Tregs were significantly increased in tumor samples compared to blood samples (Tregs: 19.13% vs. 8.286%, P=0.0008; CD137+ Tregs: 9.47% vs. 6.05%; P=0.0049; Figures 4B, C). This evidence concerns the gene TNFRSF9 and neoplasm.